0QAJ Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.50 |
| 52 Week High | €2.37 |
| 52 Week Low | €0.51 |
| Beta | 0.24 |
| 1 Month Change | -0.73% |
| 3 Month Change | 108.03% |
| 1 Year Change | 27.29% |
| 3 Year Change | -48.85% |
| 5 Year Change | -85.79% |
| Change since IPO | -86.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QAJ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.5% | 1.7% | 0.6% |
| 1Y | 27.3% | -15.0% | 3.5% |
Return vs Industry: 0QAJ exceeded the UK Biotechs industry which returned -12.9% over the past year.
Return vs Market: 0QAJ exceeded the UK Market which returned 3.4% over the past year.
Price Volatility
| 0QAJ volatility | |
|---|---|
| 0QAJ Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: 0QAJ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QAJ's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 106 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| 0QAJ fundamental statistics | |
|---|---|
| Market cap | €204.53m |
| Earnings (TTM) | -€100.10m |
| Revenue (TTM) | €3.08m |
Is 0QAJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QAJ income statement (TTM) | |
|---|---|
| Revenue | US$3.50m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.50m |
| Other Expenses | US$117.15m |
| Earnings | -US$113.65m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,249.99% |
| Debt/Equity Ratio | 0% |
How did 0QAJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 05:29 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DBV Technologies S.A. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jean-Jacques Le Fur | Bryan Garnier & Co |
| Liisa Bayko | Citizens JMP Securities, LLC |